GRI Bio Inc. (GRI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
GRI Bio Inc. stock (GRI) is currently trading at $2.37. Analyst consensus price target for GRI is $160.00. WallStSmart rates GRI as Sell.
- GRI PE ratio analysis and historical PE chart
- GRI PS ratio (Price-to-Sales) history and trend
- GRI intrinsic value — DCF, Graham Number, EPV models
- GRI stock price prediction 2025 2026 2027 2028 2029 2030
- GRI fair value vs current price
- GRI insider transactions and insider buying
- Is GRI undervalued or overvalued?
- GRI Bio Inc. financial analysis — revenue, earnings, cash flow
- GRI Piotroski F-Score and Altman Z-Score
- GRI analyst price target and Smart Rating
GRI Bio Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
GRI Bio Inc. (GRI) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
GRI Bio Inc. (GRI) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
GRI Bio Inc. (GRI) Areas to Watch (3)
Company is destroying shareholder value
Very low institutional interest at 0.15%
Micro-cap company with very limited liquidity and high volatility
GRI Bio Inc. (GRI) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.57) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Institutional Own., Market Cap. Profitability pressure is visible in Return on Equity at -238.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -238.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GRI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GRI's Price-to-Sales ratio of 0.03x trades at a deep discount to its historical average of 0.1x (0th percentile). The current valuation is 75% below its historical high of 0.14x set in Jul 2025, and 16% above its historical low of 0.03x in Feb 2026. Over the past 12 months, the PS ratio has compressed from ~0.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for GRI Bio Inc. (GRI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
GRI Bio Inc. operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 8M in cash.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact GRI Bio Inc..
Bottom Line
GRI Bio Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About GRI Bio Inc.(GRI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
GRI Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing patient care through its proprietary microbiome technology platform. With a strong emphasis on developing innovative therapies specifically targeting unmet medical needs in immunology and oncology, GRI Bio strives to tackle the underlying causes of diseases rather than just their symptoms. The company has established a robust pipeline of product candidates and strategic research partnerships, positioning it for notable growth and a leadership role in the burgeoning field of microbiome therapeutics. Committed to enhancing patient outcomes, GRI Bio is well-equipped to make significant contributions to the future of healthcare solutions.